This cluster groups 2 independently calculated changes: Cash & equivalents changed across a low base; Operating cash flow increased 11.4%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTArtiva Biotherapeutics, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents changed across a low base; Operating cash flow increased 11.4%.
2 evidence-backed componentsShares outstanding changed +100.2% from the comparable as-filed period. The change ranks at the 100th percentile of 5 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ARTV · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-389514SEC ↗4Sep 11, 2026Period Sep 9, 20260001193125-26-389512SEC ↗4Sep 11, 2026Period Sep 9, 20260001193125-26-389511SEC ↗4Sep 11, 2026Period Sep 9, 20260001193125-26-389510SEC ↗8-KSep 11, 2026Period Sep 8, 20260001193125-26-389308SEC ↗4Sep 9, 2026Period Sep 8, 20260001193125-26-386431SEC ↗4Sep 8, 2026Period Sep 8, 20260001231919-26-001152SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 9, 2026Filed Sep 11, 2026 | Miralles Gines DiegoPresident & Head of R&D | Grant Or AwardDirect | 45,000 | $0 | $0 | Form 4 ↗ |
| Sep 9, 2026Filed Sep 11, 2026 | Miralles Gines DiegoPresident & Head of R&D | Grant Or AwardDirect | 135,000 | $0 | $0 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 9, 2026 | Aslan FredChief Executive Officer | Open Market SaleDirect | 23,429 | $11 | $255,746 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 8, 2026 | HOUGEN ELIZABETH LDirector | Grant Or AwardDirect | 13,750 | $0 | $0 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 8, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Free-cash-flow proxy changed +13.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating income changed -17.9% from the comparable as-filed period.
Operating cash flow changed +11.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current assets changed +136.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current ratio changed +74.5% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Total assets changed +117.6% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-385419| Stoppel LauraDirector |
| Grant Or AwardDirect |
| 13,750 |
| $0 |
| $0 |
| Form 4 ↗ |
| Sep 8, 2026Filed Sep 8, 2026 | RA CAPITAL MANAGEMENT, L.P.Director | Grant Or AwardIndirect | 13,750 | $0 | $0 | Form 4 ↗ |
| Sep 3, 2026Filed Sep 4, 2026 | Horan ChristopherChief Tech Operations Officer | Open Market SaleDirect | 10,366 | $11 | $115,638 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 31, 2026 | Banerjee SubhashisChief Medical Officer | Option ExerciseDirect | 5,306 | $2 | $10,188 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 31, 2026 | Banerjee SubhashisChief Medical Officer | Open Market SaleDirect | 8,222 | $12 | $98,736 | Form 4 ↗ |
| Aug 27, 2026Filed Aug 31, 2026 | Banerjee SubhashisChief Medical Officer | Option ExerciseDirect | 5,306 | $0 | $0 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 19, 2026 | Banerjee SubhashisChief Medical Officer | Option ExerciseDirect | 429 | $2 | $824 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 19, 2026 | Banerjee SubhashisChief Medical Officer | Open Market SaleDirect | 429 | $12 | $5,148 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 19, 2026 | Banerjee SubhashisChief Medical Officer | Option ExerciseDirect | 429 | $0 | $0 | Form 4 ↗ |